ZA938171B - Conjugate vaccine against group B Streptococcus. - Google Patents

Conjugate vaccine against group B Streptococcus.

Info

Publication number
ZA938171B
ZA938171B ZA938171A ZA938171A ZA938171B ZA 938171 B ZA938171 B ZA 938171B ZA 938171 A ZA938171 A ZA 938171A ZA 938171 A ZA938171 A ZA 938171A ZA 938171 B ZA938171 B ZA 938171B
Authority
ZA
South Africa
Prior art keywords
streptococcus
vaccine against
conjugate vaccine
against group
group
Prior art date
Application number
ZA938171A
Other languages
English (en)
Inventor
James L Michel
Dennis L Kasper
Frederick M Ausubel
Lawrence C Madoff
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital filed Critical Gen Hospital Corp
Publication of ZA938171B publication Critical patent/ZA938171B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA938171A 1992-11-02 1993-11-02 Conjugate vaccine against group B Streptococcus. ZA938171B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02

Publications (1)

Publication Number Publication Date
ZA938171B true ZA938171B (en) 1995-03-07

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA938171A ZA938171B (en) 1992-11-02 1993-11-02 Conjugate vaccine against group B Streptococcus.

Country Status (14)

Country Link
EP (1) EP0669985A1 (xx)
JP (1) JPH08505282A (xx)
KR (1) KR100349331B1 (xx)
AU (1) AU689452B2 (xx)
CA (1) CA2146926A1 (xx)
FI (1) FI951979A (xx)
HU (1) HU220198B (xx)
IL (1) IL107458A0 (xx)
NO (1) NO951629L (xx)
NZ (1) NZ258684A (xx)
PL (1) PL177302B1 (xx)
RU (1) RU2209247C2 (xx)
WO (1) WO1994010317A2 (xx)
ZA (1) ZA938171B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
EP1100920A2 (en) * 1998-07-27 2001-05-23 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
EA009885B1 (ru) * 1998-12-22 2008-04-28 Майкросайенс Лимитед Применение пептидов бактерий streptococcus группы b, кодирующего их полинуклеотида, вакцина и антитело
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
GB9910375D0 (en) 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
JP4102186B2 (ja) 2000-10-13 2008-06-18 アイディー バイオメディカル コーポレイション グループｂストレプトコッカスのｂｖｈ−ａ２及びｂｖｈ−ａ３抗原
BRPI0408167B1 (pt) * 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
CA2684494C (en) 2007-04-16 2016-07-05 Lunds Universitets Utvecklingsaktiebolag Fusion protein capable of eliciting protective immunity against group b streptococcus
AU2009286956B2 (en) 2008-08-28 2012-12-06 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
CA3001433A1 (en) 2015-10-21 2017-04-27 Minervax Aps Immunogenic fusion protein
WO2017114655A1 (en) 2015-12-30 2017-07-06 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
WO2018229708A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750139T2 (de) * 1986-04-16 1994-10-06 Brigham & Womens Hospital Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein

Also Published As

Publication number Publication date
CA2146926A1 (en) 1994-05-11
KR950704492A (ko) 1995-11-20
NO951629D0 (no) 1995-04-28
RU2209247C2 (ru) 2003-07-27
JPH08505282A (ja) 1996-06-11
NZ258684A (en) 1997-04-24
AU5665494A (en) 1994-05-24
AU689452B2 (en) 1998-04-02
HUT70981A (en) 1995-11-28
EP0669985A1 (en) 1995-09-06
NO951629L (no) 1995-07-03
PL308555A1 (en) 1995-08-21
FI951979A0 (fi) 1995-04-26
IL107458A0 (en) 1994-02-27
KR100349331B1 (ko) 2003-01-06
FI951979A (fi) 1995-06-29
WO1994010317A3 (en) 1994-07-07
WO1994010317A2 (en) 1994-05-11
HU220198B (hu) 2001-11-28
PL177302B1 (pl) 1999-10-29

Similar Documents

Publication Publication Date Title
EP0634459A3 (de) Formulierungen.
CZ197595A3 (en) Vaccine preparations
EP0597463A3 (en) Thermotherapiesonde.
GR3022463T3 (en) 1-H-3-aryl-pyrrolidin-2,4-dion-derivatives
EP0580285A3 (en) Auto-reclosers.
ZA926733B (en) 1,2-Dihydro-2-oxopyridines.
EP0604748A3 (de) Trokarhülse.
ZA938171B (en) Conjugate vaccine against group B Streptococcus.
ZA937034B (en) Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
EP0572808A3 (de) Antiblockierregelsystem.
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
ZA927999B (en) Thickening agents.
EP0595970A4 (en) IMPROVED VACCINE.
EP0599191A3 (en) Engine speed control circuit.
EP0592354A3 (de) Vakuum-Zentrifuge.
ZA933848B (en) Pyridyl-1,2,5-oxadiazolecarboxamide-2-oxides
AU4970193A (en) IPNV vaccine
GB9320943D0 (en) Peptide-protein conjugate vaccines having anionic spacers
AU5626998A (en) Conjugate vaccine against group B Streptococcus
ZA939564B (en) Vaccines.
EP0681480A4 (en) RECOGNIN VACCINES.
SG48106A1 (en) Pneumococcal polyaccharide conjugate vaccine
ZA93236B (en) Babesial rhoptry antigens.
EP0647139A4 (en) CONJUGATE VACCINE FROM ADHESINE OLIGOSACCHARIDE AGAINST -i (HEMOPHILUS IN FLUENZA).
ZA967198B (en) Vaccines.